STOCK TITAN
  1. Home
  2. News
  3. KRTX

Karuna Therapeutics, Inc. - KRTX STOCK NEWS

Welcome to our dedicated page for Karuna Therapeutics news (Ticker: KRTX), a resource for investors and traders seeking the latest updates and insights on Karuna Therapeutics stock.

Karuna Therapeutics, Inc. (NASDAQ: KRTX) is an innovative clinical-stage biopharmaceutical company dedicated to developing groundbreaking therapies for neuropsychiatric conditions with significant unmet medical needs. Our flagship product candidate, KarXT, is an oral modulator of muscarinic receptors, targeting both the central nervous system (CNS) and various peripheral tissues. KarXT uniquely combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS.

Our pipeline capitalizes on the broad therapeutic potential of KarXT. We have assembled a team with extensive expertise in the research, development, and commercialization of CNS agents. This includes deep familiarity with the biology of neuropsychiatric disorders such as schizophrenia and Alzheimer's disease, and the role of muscarinic receptors in their potential treatment.

Recently, Karuna Therapeutics has achieved significant milestones in advancing KarXT through various stages of clinical trials, demonstrating promising results in improving symptoms of schizophrenia and other neuropsychiatric conditions. We are committed to leveraging our deep understanding of CNS biology to develop a pipeline of novel therapies aimed at addressing the pressing needs of patients with debilitating mental health conditions.

In addition to our scientific endeavors, we actively seek strategic partnerships and collaborations to accelerate the development and commercialization of our therapies. Our financial condition remains robust, supported by strategic investments and a clear focus on driving innovation in neuropsychiatric treatment.

Stay updated with the latest news and developments from Karuna Therapeutics, Inc. as we continue our mission to transform the treatment landscape for neuropsychiatric disorders.

News

Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update

Rhea-AI Summary
Karuna Therapeutics, Inc. announces the NDA review for KarXT for schizophrenia treatment, Phase 3 trial results, key pipeline highlights, leadership appointments, financial results, and business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
earnings
-
News

PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion

Rhea-AI Summary
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced that its Founded Entity, Karuna Therapeutics, Inc., and Bristol Myers Squibb (NYSE: BMY) have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
acquisition
-
News

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics

Rhea-AI Summary
Bristol Myers Squibb (BMY) will acquire Karuna Therapeutics, Inc. (KRTX) for $14.0 billion, aiming to enhance their growth and diversify the portfolio in the neuroscience space. The transaction is expected to close in the first half of 2024, with KarXT, a first-in-class treatment for schizophrenia and Alzheimer's disease psychosis, as the key asset.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
acquisition
News

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics

Rhea-AI Summary
Bristol Myers Squibb (BMY) to Acquire Karuna Therapeutics, Inc. (KRTX) for $14 Billion, Expanding Its Portfolio in Neuroscience
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
acquisition
-
News

Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia

Rhea-AI Summary
Karuna Therapeutics, a biopharmaceutical company (NASDAQ: KRTX), announced statistically significant and clinically meaningful improvements in positive and negative symptoms of schizophrenia with their drug KarXT. The dual M1/M4 muscarinic agonist showed a distinct tolerability profile and a potential to redefine the treatment landscape for schizophrenia. The Phase 3 EMERGENT-2 trial published in The Lancet demonstrated a 9.6-point reduction in PANSS total score compared to placebo, with a Prescription Drug User Fee Act (PDUFA) action date of September 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
acquisition clinical trial
-
News

PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia

Rhea-AI Summary
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
News

Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia

Rhea-AI Summary
Karuna Therapeutics, Inc. (NASDAQ: KRTX) has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for KarXT (xanomeline-trospium) for the treatment of schizophrenia in adults, with a Prescription Drug User Fee Act (PDUFA) date of September 26, 2024. If approved, KarXT would represent the first new pharmacological approach to treating schizophrenia in several decades. The application is supported by positive data from the EMERGENT clinical trial program showing KarXT is associated with significant improvements in schizophrenia symptoms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
-
News

PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia

Rhea-AI Summary
Karuna Therapeutics (KRTX) announced positive results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of KarXT on 24-hour ambulatory blood pressure in adults with schizophrenia. KarXT demonstrated a mean change from baseline to week 8 in 24-hour ambulatory systolic blood pressure of -0.59 mmHg, ruling out a clinically meaningful increase in blood pressure. The trial showed that KarXT was generally well tolerated, with a side effect profile consistent with prior trials in the EMERGENT program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.77%
Tags
clinical trial
-
News

Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia

Rhea-AI Summary
Karuna Therapeutics, Inc. (NASDAQ: KRTX) announced positive results from its Phase 1b trial showing that KarXT (xanomeline-trospium) did not cause clinically meaningful increases in blood pressure in adults with schizophrenia. The trial demonstrated a mean decrease of -0.59 mmHg in 24-hour ambulatory systolic blood pressure, consistent with prior trials. The data confirms the cardiovascular safety profile of KarXT and will be included in the NDA Day 120 safety update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.77%
Tags
clinical trial
News

Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates

Rhea-AI Summary
Karuna Therapeutics announced the submission of a New Drug Application (NDA) to the FDA for KarXT for the treatment of schizophrenia. They also initiated Phase 3 trials for the treatment of psychosis in Alzheimer’s disease. The company expects $1.3 billion in cash to fund operations through 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
earnings

FAQ

What is Karuna Therapeutics, Inc.?

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neuropsychiatric conditions.

What is KarXT?

KarXT is Karuna Therapeutics' lead product candidate, an oral modulator targeting muscarinic receptors in the CNS and peripheral tissues.

What conditions does KarXT aim to treat?

KarXT aims to treat neuropsychiatric disorders such as schizophrenia and Alzheimer's disease.

What makes KarXT unique?

KarXT uniquely combines xanomeline, a muscarinic agonist, with trospium, a muscarinic antagonist, to stimulate muscarinic receptors in the CNS.

Who makes up the team at Karuna Therapeutics?

The team at Karuna Therapeutics includes experts in CNS agent research, development, and commercialization, with deep knowledge of neuropsychiatric disorders.

How is Karuna Therapeutics progressing with KarXT?

Karuna Therapeutics has achieved significant milestones in advancing KarXT through various stages of clinical trials, showing promising results.

What is the financial condition of Karuna Therapeutics?

Karuna Therapeutics maintains a robust financial condition supported by strategic investments and a focus on innovation in neuropsychiatric treatment.

Does Karuna Therapeutics have any strategic partnerships?

Yes, Karuna Therapeutics actively seeks strategic partnerships and collaborations to accelerate the development and commercialization of its therapies.

Where can I find the latest news about Karuna Therapeutics?

The latest news and updates about Karuna Therapeutics can be found on their official website and stock market websites such as StockTitan.

What is the ticker symbol for Karuna Therapeutics, Inc.?

The ticker symbol for Karuna Therapeutics, Inc. is KRTX.

Stock KRTX logo
Karuna Therapeutics, Inc.

Nasdaq:KRTX

KRTX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

KRTX Stock Data

12.60B
36.27M
4.99%
86.32%
5.17%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston